Santhera Price To Sales Ratio from 2010 to 2026
| SANN Stock | CHF 16.46 0.46 2.88% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 4.62 | Current Value 4.39 | Quarterly Volatility 67.24495329 |
Check Santhera Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Santhera Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.9 M, Interest Expense of 24.4 M or Selling General Administrative of 12.1 M, as well as many indicators such as Price To Sales Ratio of 4.39, Dividend Yield of 0.0 or PTB Ratio of 3.78. Santhera financial statements analysis is a perfect complement when working with Santhera Pharmaceuticals Valuation or Volatility modules.
Santhera | Price To Sales Ratio |
The evolution of Price To Sales Ratio for Santhera Pharmaceuticals Holding provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Santhera Pharmaceuticals compares to historical norms and industry peers.
Latest Santhera Pharmaceuticals' Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Santhera Pharmaceuticals Holding over the last few years. Price to Sales Ratio is figured by comparing Santhera Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Santhera Pharmaceuticals sales, a figure that is much harder to manipulate than other Santhera Pharmaceuticals Holding multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Santhera Pharmaceuticals' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Santhera Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 4.92 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
Santhera Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 31.94 | |
| Coefficient Of Variation | 210.51 | |
| Mean Deviation | 46.77 | |
| Median | 4.62 | |
| Standard Deviation | 67.24 | |
| Sample Variance | 4,522 | |
| Range | 256 | |
| R-Value | (0.53) | |
| Mean Square Error | 3,476 | |
| R-Squared | 0.28 | |
| Significance | 0.03 | |
| Slope | (7.04) | |
| Total Sum of Squares | 72,350 |
Santhera Price To Sales Ratio History
About Santhera Pharmaceuticals Financial Statements
Santhera Pharmaceuticals investors use historical fundamental indicators, such as Santhera Pharmaceuticals' Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Santhera Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 4.62 | 4.39 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Santhera Stock Analysis
When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.